MangoRx Accepting Pre Orders For Its "PRIME", by MangoRx, Powered By Kyzatrex FDA Approved Oral Testosterone Replacement Therapy Product
Portfolio Pulse from Benzinga Newsdesk
Mangoceuticals, Inc. (NASDAQ:MGRX), also known as MangoRx, is launching 'PRIME', an oral testosterone replacement therapy powered by Kyzatrex. The Dallas-based telemedicine company is offering 2 months of free 'PRIME' to the first 1,000 male subscribers. This promotion is part of a broader marketing strategy, including a marquee sponsorship with Barstool Sports. PRIME is one of only three FDA-approved oral TRT treatments, promising enhanced vitality, mood, cognition, and physical performance. It will be priced at $199/month, with a 10% discount for subscribers of other MangoRx products.
February 05, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mangoceuticals, Inc. is launching 'PRIME', an oral testosterone replacement therapy, with a promotional offer and a marketing partnership with Barstool Sports. PRIME is set to enhance MangoRx's product lineup, targeting a significant market with minimal competition.
The launch of 'PRIME' represents a significant expansion for MangoRx into a new market with high potential and low competition. The promotional offer and partnership with Barstool Sports are likely to generate substantial interest and customer acquisition in the short term. Given the innovative nature of the product and the strategic marketing efforts, there is a positive outlook for MGRX's stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100